We consider this an important finding as PLK1 silencing is already part of an integrated oncolytic adenovirus approach currently being studied in mice models of orthotopic gastric carcinoma [148] and has promise due to the lack of a reported measurable immune response of siRNA-based therapeutics [149]. The gene discussed is PLK1; the disease is gastric carcinoma.